<- Go Home
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Market Cap
$318.3B
Volume
5.3M
Cash and Equivalents
$7.3B
EBITDA
$25.6B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$39.1B
Profit Margin
70.33%
52 Week High
$207.32
52 Week Low
$153.58
Dividend
3.64%
Price / Book Value
52.76
Price / Earnings
62.75
Price / Tangible Book Value
-3.32
Enterprise Value
$382.3B
Enterprise Value / EBITDA
14.74
Operating Income
$17.3B
Return on Equity
56.41%
Return on Assets
7.72
Cash and Short Term Investments
$7.3B
Debt
$71.3B
Equity
$6.1B
Revenue
$55.5B
Unlevered FCF
$19.4B
Sector
Biotechnology
Category
N/A
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick Premium